Assorted News from the Last Two Weeks: National Cancer Institute’s CCDI Molecular Characterization Initiative adds rare tumors. Study provides first in-depth look at major mix-ups
Children, adolescents, and young adults (AYAs) with newly diagnosed rare tumors are now eligible to enroll in the CCDI Molecular Characterization Initiative. Rare tumors are
Assorted News from the Last Two Weeks: The Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of children aged 1 year or
Assorted News from the Last Week: Leukemia and Lymphoma Society’s (LLS) has launched its Dare to Dream Project as an extension of itself Children’s Initiative.
The Molecular Targets Platform is an NCI-supported instance of the Open Targets Platform with a focus on preclinical pediatric oncology data. It is a tool
Assorted News from the Last Two Weeks: The CCDI Molecular Targets Platform is the National Cancer Institute’s instance of the Open Targets Platform, specific to
[vc_row][vc_column][vc_column_text]Update from our colleagues at the Alliance for Childhood Cancer (July 28, 2022): The Senate Appropriations Committee included language to fund the Childhood Cancer STAR
Assorted News from Last Week: The Biden administration has selected Monica Bertagnolli, a renowned surgical oncologist, as the next director of the National Cancer Institute.
Assorted News from Last Week: Researchers have identified the child cancer patients at greatest risk of developing life-threatening infections, in a crucial step towards the
Assorted News from Last Week: Three things to know if your child is diagnosed with cancer. CNN Correspondent Rene Marsh tells the story of her pediatric
